Statistically significant differences in CD31 staining were observed between luminal A and Her2+ breast cancers (p < 0.05), as well as between luminal A and triple-negative breast cancers (p < 0.005, Figure 4). This evidence concerns the gene ERBB2 and breast carcinoma.